Karen E A Burns1,2,3, Clara Juando Prats3,4, Maria Maione5, Mary Lanceta5, Celia Zubrinich6, Lianne Jeffs3,5, Orla M Smith2,3,4. 1. 1 Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada. 2. 2 Division of Critical Care Medicine, and. 3. 3 Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada. 4. 4 Bloomberg School of Nursing, University of Toronto, Toronto, Ontario, Canada. 5. 5 Professional Practice-Nursing/Clinical Research Portfolio, St. Michael's Hospital, Toronto, Ontario, Canada; and. 6. 6 Allergy and Asthma, the Alfred Hospital, Melbourne, Victoria, Australia.
Abstract
RATIONALE: Recruitment in critical care research differs from other contexts in important ways: patients lack decision-making capacity, uncertainty exists regarding patient prognosis, and critical illnesses are often associated with appreciable morbidity and mortality. OBJECTIVES: We aimed to describe the experiences of surrogate decision makers (SDMs) in being approached for consent for critically ill patients to participate in research. METHODS: A multicenter, qualitative study involving semistructured interviews with 26 SDMs, who provided or declined surrogate consent for research participation, at 5 Canadian centers nested within a multicenter observational study of research recruitment practices. Transcripts were reviewed by three qualitative researchers, and data were analyzed using grounded theory and a narrative critical analysis. MEASUREMENTS AND MAIN RESULTS: SDMs were guided by an overarching desire for the patient to live. Surrogate research decision-making involved three sequential stages: (1) being approached; (2) reflecting on participation; and (3) making a decision. In stage 1, SDMs identified factors (their expectations, how they were approached, the attributes of the person approaching, and study risks and benefits) that characterized their consent encounter and affirmed a preference to be approached in person. If SDMs perceived the risk of participation to be too high or felt patients may not benefit from participation, they did not contemplate further. In stage 2, SDMs who knew the patient's wishes or had a deeper understanding of research prioritized the patient's wishes and the perceived benefits of participation. Without this information, SDMs prioritized obtaining more and better care for the patient, considered what was in their mutual best interests, and valued healthcare professional's knowledge. Trust in healthcare professionals was essential to proceeding further. In stage 3, SDMs considered six factors in rendering decisions. CONCLUSIONS: SDMs engaged in three sequential stages and considered six factors in making surrogate decisions for research participation. Surrogates' assessments of the risks and benefits of participation and their trust in healthcare professionals were critical factors in research decision-making. By conceptualizing surrogate decision-making for research in stages, future research can develop and test procedures to enhance the surrogate research decision-making process.
RATIONALE: Recruitment in critical care research differs from other contexts in important ways: patients lack decision-making capacity, uncertainty exists regarding patient prognosis, and critical illnesses are often associated with appreciable morbidity and mortality. OBJECTIVES: We aimed to describe the experiences of surrogate decision makers (SDMs) in being approached for consent for critically illpatients to participate in research. METHODS: A multicenter, qualitative study involving semistructured interviews with 26 SDMs, who provided or declined surrogate consent for research participation, at 5 Canadian centers nested within a multicenter observational study of research recruitment practices. Transcripts were reviewed by three qualitative researchers, and data were analyzed using grounded theory and a narrative critical analysis. MEASUREMENTS AND MAIN RESULTS: SDMs were guided by an overarching desire for the patient to live. Surrogate research decision-making involved three sequential stages: (1) being approached; (2) reflecting on participation; and (3) making a decision. In stage 1, SDMs identified factors (their expectations, how they were approached, the attributes of the person approaching, and study risks and benefits) that characterized their consent encounter and affirmed a preference to be approached in person. If SDMs perceived the risk of participation to be too high or felt patients may not benefit from participation, they did not contemplate further. In stage 2, SDMs who knew the patient's wishes or had a deeper understanding of research prioritized the patient's wishes and the perceived benefits of participation. Without this information, SDMs prioritized obtaining more and better care for the patient, considered what was in their mutual best interests, and valued healthcare professional's knowledge. Trust in healthcare professionals was essential to proceeding further. In stage 3, SDMs considered six factors in rendering decisions. CONCLUSIONS: SDMs engaged in three sequential stages and considered six factors in making surrogate decisions for research participation. Surrogates' assessments of the risks and benefits of participation and their trust in healthcare professionals were critical factors in research decision-making. By conceptualizing surrogate decision-making for research in stages, future research can develop and test procedures to enhance the surrogate research decision-making process.
Entities:
Keywords:
consent; proxy; qualitative evaluation; research ethics; surrogate decision maker
Authors: Zhe Kang Law; Jason P Appleton; Polly Scutt; Ian Roberts; Rustam Al-Shahi Salman; Timothy J England; David J Werring; Thompson Robinson; Kailash Krishnan; Robert A Dineen; Ann Charlotte Laska; Philippe A Lyrer; Juan Jose Egea-Guerrero; Michal Karlinski; Hanne Christensen; Christine Roffe; Daniel Bereczki; Serefnur Ozturk; Jegan Thanabalan; Ronan Collins; Maia Beridze; Alfonso Ciccone; Lelia Duley; Angela Shone; Philip M Bath; Nikola Sprigg Journal: Stroke Date: 2021-12-01 Impact factor: 7.914
Authors: Alison E Turnbull; Mohamed D Hashem; Anahita Rabiee; An To; Caroline M Chessare; Dale M Needham Journal: PLoS One Date: 2017-05-25 Impact factor: 3.240